Company Products Research Collaborators Regulatory Investor Relations Contact Us  


Kelly, dumped by her owners, overcomes distemper, lands in loving home: People and their pets
September 02, 2015

BEREA, Ohio -- Such a tiny thing she is. Such a huge heart she has - one that she shares with everybody.

When we met her, Kelly greeted Pam and me as if we were long, lost friends. We didn't know it then, but that's how she treats everyone: humans, dogs - cats, even. (Squirrels, rabbits, and whatnot are another story. She's as sweet as pie. But she is, after all, a dog).

Her story is far too common: She was dumped by her initial "owner(s)" while she was pregnant. And, although it wasn't immediately apparent, because her initial human family had failed to have her vaccinated (as well as neglecting to have her spayed), she suffered from distemper (a life-threatening illness), too.

Word spread in the animal-welfare community that help was urgently needed, and Save Ohio Strays - which routinely rescues animals on "death row" -- answered the call. And so it was that Kelly journeyed from Gallia County in southern Ohio to Medina County, over 200 road miles to the northeast. (Referencing her home county, SOS temporarily named her Gailee, When we adopted her, Pam and I gave her the permanent name: Kelly.)

SOS fosters Sandy and Michael took the little critter into their home, and saw to it that she received life-saving medical treatment. They also cared for her pups (six in all; five of whom survived the distemper ordeal).

Kelly's prognosis is good. Lab-test readings are encouraging, an experimental treatment having worked wonders for her. But there are no guarantees; while the distemper is unlikely to return, the extent of neurological damage (if any) might not be apparent for some time.

Those who've met Kelly understand why so many people worked so hard to save her. She's a real sweetheart. In that regard, she's like so many other wonderful animals - loving companions who are too often cast aside, for reasons that are unfathomable to decent folk.

Pam and I are grateful to all who had a hand in Kelly's salvation. She is a very welcome addition to our family. Should you ever have the good fortune to meet her, be prepared to be enveloped in the warmth of her affection. She seems to have an endless supply.

Auburn University and Nuovo Biologics Announce Academic-Biotech Collaboration
May 29, 2015

Researchers from Auburn University's Research Initiative in Cancer (AURIC), and Nuovo Biologics LLC, of Davie, Fl., have announced a partnership to develop new therapies for cancer.

Initially targeting canine malignant melanoma, or skin cancer, a deadly tumor that affects many dogs, the team will be testing Nuovo’s innovative anti-cancer peptide drug MMX for its ability to treat these tumors.

The National Institutes for Health recently awarded a grant funded by the U.S. Food and Drug Administration to support a clinical trial of the new peptide treatment. According to Dr. Bruce Smith, Director of AURIC and leader of the Auburn component of the research effort, the clinical trial will begin to recruit patients as early as June or July.

Dr. Jay Yourist, C.E.O. of Nuovo Biologics, Auburn's biotech partner, said, “this clinical trial represents the next step in moving MMX forward to FDA approval.”

In addition to the planned research with Nuovo, AURIC scientists are pursuing a wide variety of interdisciplinary cancer research, ranging from identifying the basic mechanisms that make normal cells become cancerous to a variety of new approaches to treating cancers. Funding for AURIC research is provided by the State of Alabama, Federal research grants, funding from private organizations and donations from individuals.

Both AURIC and Nuovo Biologics take a One-Health/One-Medicine approach to cancer treatment, allowing discoveries in one species to be translated to other species. This latest partnership builds on the collaborative approach Nuovo has implemented with academic institutions, researchers, and veterinarians across the country.

Nuovo Biologics Participates in NAVC
February 15, 2015

Nuovo Biologics C.E.O., Dr. Jay Yourist, along with Business Development Vice President, Stuart Rose, and several Board members, attended the North American Veterinarian Conference, East for the annual gathering in Orlando, Florida.

Since its inception, Dr. Yourist and various members of Nuovo's management and investment teams have participated in the gathering. "We have used the opportunity to meet with our friends and supporters within the veterinary community. "Further, according to Dr. Yourist, "this allows Nuovo Biologics to stay abreast of new and emerging technologies and plan for marketing and distribution after our anticipated FDA approval."

Nuovo Biologics, a biopharmaceutical company, has obtained two Investigational New Animal Drug (INAD) numbers from the FDA for for a broad-spectrum antiviral drug for treating viral diseases in companion animals and for the treatment of stages II and III canine oral malignant melanoma.

Nuovo Partners With Auburn University
December 30, 2014

Nuovo Biologics, in partnership with its research collaborators at Auburn University College of Veterinary Medicine, have received an NIH grant to fund a ‘Reasonable Expectation of Efficacy’ (RXE) clinical trial to evaluate effectiveness of MMX on canines diagnosed with oral canine malignant melanoma stages II & III.

Canine Malignant Melanoma is often fatal to dogs, and tens of thousands of cases are reported every year. MMX is Nuovo Biologics' anti-tumor drug formulation for which the Company has a Minor Use Designation from the FDA for Oral Canine Malignant Melanoma. This status is similar to an "orphan drug" status for human drugs. The study is expected to start later this year.

Nuovo Signs Major Research Agreement with NIH/NIAID (National Institute of Allergy & Infectious Disease)
November 27, 2014

The National Institute of Health's National Institute for Allergy and Infectious Diseases signed a pre-clinical evaluation agreement with Nuovo Biologics. This agreement sets the stage for a collaboration between Nuovo Biologics and the NIAID to test various emerging pathogens.

The NIH will now evaluate Nuovo's peptide technology to inhibit various bioweapon and public health pathogen threats. This will provide important insight into PVX and its effectiveness against many types of viruses, including some with significant public health consequences. The NIH/NIAID has some of the largest, most comprehensive and well-respected outsourced research laboratories in the world. These facilities have access to certain specialized containment laboratories and virus samples, expanding the reach and capabilities of Nuovo and its current collaborators.


First - Previous - Next - Last Showing 1 to 5 of 37